Mirum Pharmaceuticals' experimental hepatitis drug reduces virus levels in late-stage study

{"#Chronic_Hepatitis_Delta_Virus":"Chronic hepatitis delta virus (HDV) is a rare liver infection that can only occur in people already infected with hepatitis B. The disease often leads to severe symptoms and can progress to significant liver damage and even death.","##Mirum_Pharmaceuticals_Study":"Mirum Pharmaceuticals conducted a late-stage study of its experimental monoclonal antibody, brelovitug, which targets the hepatitis B surface antigen. The study showed promising results at 24 weeks, with 56% of patients who received 300 milligrams and 45% of patients who received 900 milligrams achieving both a reduction in hepatitis D virus levels and normal liver enzyme levels.","##Safety_Profile":"The treatment was well tolerated across all dose groups, and the safety profile was consistent with previously reported data. The company plans to present the full results from the study at an upcoming medical congress and expects to submit a marketing application for brelovitug to the US FDA in the first half of 2027."}